

Resource Summary Report

Generated by [Kravitz](#) on Sep 10, 2026

Leica: Aperio AT2 scanner

RRID:SCR_021256

Type: Tool

Proper Citation

Leica: Aperio AT2 scanner (RRID:SCR_021256)

Resource Information

URL: <https://www.leicabiosystems.com/digital-pathology/scan/aperio-at2/>

Proper Citation: Leica: Aperio AT2 scanner (RRID:SCR_021256)

Description: Digital whole slide scanner.400 slide capacity brightfield scanner. High throughput with small footprint. 2x3 slide option available.Aperio AT2 runs on Microsoft Windows 10 operating system.

Synonyms: Aperio AT2

Resource Type: instrument resource

Keywords: Digital whole slide scanner, scanner, instrument, equipment, USE Dit

Resource Name: Leica: Aperio AT2 scanner

Resource ID: SCR_021256

Alternate IDs: Model_Number_Aperio_AT2

Record Creation Time: 20220129T080354+0000

Record Last Update: 20260905T132937+0000

Ratings and Alerts

No rating or validation information has been found for Leica: Aperio AT2 scanner.

No alerts have been found for Leica: Aperio AT2 scanner.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 28 mentions in open access literature.

Listed below are recent publications. The full list is available at [Kravitz](#) .

Kastinen M, et al. (2026) Unraveling the Effects and Characteristics of Proliferating Tumor and Cytotoxic T Cells in Colorectal Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(2), 350.

Al-Azzam S, et al. (2026) Multi-omics profiling reveals microenvironmental remodeling as a key driver of house dust mite-induced lung cancer progression. *Neoplasia (New York, N.Y.)*, 73, 101275.

Pawar NR, et al. (2026) A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter SLC43A1 (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cells. *Molecular cancer therapeutics*.

Wu N, et al. (2026) Arginine deprivation enhances ASS1-negative glioblastoma radiosensitivity via epigenetic silencing of DNA repair genes. *Cell death & disease*.

Kobayashi H, et al. (2026) Netrin-1 Promotes Pancreatic Tumorigenesis and Innervation through NEO1. *Cancer research*, 86(8), 1883.

Tran B, et al. (2026) Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(14), 2850.

Buchthal J, et al. (2026) Non-invasive ovulation tracking enables genetic engineering in wild rodents. *Cell reports methods*, 6(2), 101311.

Considine JM, et al. (2026) Comparative proteomic analysis of the ECM composition of the human omentum and mesentery, the main sites of ovarian cancer metastasis. *iScience*, 29(1), 114461.

Withers HG, et al. (2025) Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM. *Cancer immunology, immunotherapy : CII*, 74(11), 332.

Shen F, et al. (2025) Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(21), 4543.

Giddabasappa A, et al. (2025) 18F-FLT PET, a Noninvasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK) Inhibitors. *Molecular cancer therapeutics*, 24(7), 1111.

Fleming Martinez AK, et al. (2025) Downregulation of Sod2 increases atypical flat lesions and dysplasia to advance pancreatic ductal adenocarcinoma. *Molecular cancer*, 24(1), 300.

Fa'ak F, et al. (2025) Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(16), 3526.

Tsimberidou AM, et al. (2025) Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(6), 965.

Kogai H, et al. (2025) Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody-Drug Conjugate with BET Protein Degradar in Colorectal, Lung, and Breast Cancer Mouse Models. *Molecular cancer therapeutics*, 24(3), 392.

Manara MC, et al. (2025) Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcoma. *Journal of experimental & clinical cancer research : CR*, 44(1), 195.

Yamada-Hara M, et al. (2025) ROR γ t Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer. *Cancer immunology research*, 13(9), 1418.

Abdullah KG, et al. (2025) Gliomas phenocopy an inborn error of metabolism to drive neuronal activity and tumor growth. *bioRxiv : the preprint server for biology*.

Low JCM, et al. (2024) Deuterium Metabolic Imaging Differentiates Glioblastoma Metabolic Subtypes and Detects Early Response to Chemoradiotherapy. *Cancer research*, 84(12), 1996.

Marshall Moscon S, et al. (2024) A common variant in the iron regulatory gene (Hfe) alters the metabolic and transcriptional landscape in brain regions vulnerable to neurodegeneration. *Journal of neurochemistry*, 168(9), 3132.